Palobiofarma has got access to FEDER funds through the support of the Ministerio de Economía y Competitividad under the program “Innpacto”, “IMLINFO”, “CDTI PID ” and “Retos” to execute the following Projects:

• “Polyfarma: New Therapies for Parkinson Disease” (IPT-2011-1048-900000)
• “Development of pharmacological chaperons modulators for the treatment of rare neuro-metabolic diseases” (IPT-2012-0561-010000)
• “Pharmaceutical development in hematological cancers classified as rare diseases through approaches based on apoptosis” (IPT-2012-0673-010000)
• “Suppression of expression of alpha-synuclein and PDE10 activity as combined therapeutic strategy for the treatment of Parkinson and improving the derived cognitive dysfunctions ” IPT-2012- 1208-300000
• “ADENOASMA: Research and development of new adenosine receptors modulators as novel drugs for the treatment of respiratory diseases” RTC-2014- 1987-1
• “Discovery and combination of new therapies for the treatment of cancer based on the modulation of epigenetics targets and adenosine receptors” RTC -2015- 3332-1
• “Clinical development and validation of biomarkers of a new oral therapy for asthma through a phase II clinical trial” RTC-2016- 4698-1
• “Cross-border network of personalized immunotherapies for non-Hodgkin lymphomes” (EFA281/16 IMLINFO (POCTEFA))
• “Clinical Trials PBF-680 Phase II”
• “Research and clinical development of two new immunotherapies for cancer treatment based on the adenosine receptor modulation” (PBF-1129, RETOS ONCO 2017).

Palobiofarma has received a grant co-financed 50% by European Regional Development Fund through the operative Program FEDER 2014-2020 of Navarra to execute the following Projects:

1. Development of new Adenosine A3 receptor antagonists for the Glaucoma treatment. (GLAUCOADENO. 0011-1365-2015-000222).
2. Clinical Development of PBF-1129: An Adenosine A2b receptor antagonist as a new treatment for the idiopathic pulmonary fibrosis. (ADENOFIBRO. 0011-1365-2016-000023).
3. Identification and bioequivalence clinical trial of a pharmaceutically acceptable salt for a new oral treatment of allergic asthma. (ADENOSALES. 0011-1365-2017-000061).
4. Clinical Development of PBF-1650: An adenosine A3 receptor antagonist as a new treatment for Psoriasis. (ADENORIASIS. 0011-1365-2017-000120).
5. Industrial research project based on the design and discovery of new PPAR-ɣ receptor antagonists for the treatment of bladder cancer. (PPAR-ɣ ANTAGONISTS. 0011-1365-2018-000050).
6. Research and preclinical development of new CD73 inhibitors for the treatment of cancer. (ADENOCANCER. 0011-1365-2018-000021).

Inveready is one of the leading early-stage venture capital companies in Spain, with five investment funds. Inveready invests in technology companies with high growth potential and innovative business models. Inveready has extensive experience in different areas, with more than 40 portfolio companies that are leaders in their respective sectors.

Fitalent (FIT Inversión en Talento SCR de Régimen Simplificado SL) es una sociedad de capital riesgo constituida a principios de 2011 e inscrita en el registro especial de la Comisión Nacional del Mercado de Valores (CNMV), que invierte en empresas de base tecnológica y con productos de éxito probado, cuyo principal activo sean las personas y el talento.

A financial instrument of the Government of Navarra to promote business projects in the region that can contribute to the region’s development. Basically, Sodena works to try and ensure all viable projects in the self-governing region of Navarra should be able to receive financing to carry them out.